June 4th 2024
The political landscapes of both the EU and UK are set to change after the latest elections, which could affect the bio/pharma industry.
May 3rd 2024
Pharmaceutical company, Nanomerics, and several companies that work with the pharmaceutical industry have been recognized by King Charles III for business achievements.
Technological advances are helping advance biologics development and manufacturing and reduce bottlenecks.
April 2nd 2024
A revised regulatory variation framework should make lifecycle management more efficient in Europe.
March 2nd 2024
Wider life sciences industries in the UK and Europe are receiving favourable financial support from governing bodies.
FDA Guides the Way to Biosimilars in the US
Has the long-awaited guidance answered all of the industry's questions?
Stepping Up the Fight Against Counterfeits
Traditionally more prevalent in less industrialised regions, counterfeit medicines are now more frequently entering the heavily regulated supply chains of EU countries.
Sustainable Investment
Pharma announces plans for the year ahead at annual JPMorgan Global Healthcare conference.
Shipping with the Enemy?
A nickel's worth of free advice to the competition could come at the expense of your bottom line.
Saving the Next Generation of Regulatory Scientists
New educational programs are key to the industry's future and to safe, available drugs.
2012: A Good, Bad or Ugly Year for Servier?
The scandal surrounding Servier's diabetes drug, Mediator, continues to unravel in France and could have implications for the whole pharmaceutical industry as the country scrutinises its regulatory systems.
Here's to a Year of Compromise
The benefits of harmonization may be on industry's wish list, but buying into change is another story.
Innovator Liability Still Not Viable After Pliva v. Mensing
Recent legal decisions have further divided generic and brand manufacturer cases.
All Systems Slow
Technology may expedite operations, but the absence of the human element could cost dearly.
European Pharma Companies Set To Surge Ahead Of US Rivals
The next two years may see a shake up in the world's current top pharmaceutical companies, with Pfizer likely to be the only US firm to remain in the top five by sales.
Buzz Off the Product
Cleanliness is crucial, even if zapping and trapping is necessary to reduce product contamination.
Supporting Innovation Requires Consistency and Vision
Political leaders need to consider the impact of the biopharmaceutical industry on the economy.
Developing and Sustaining a Quality Culture
Employee training-at all levels-is crucial for moving forward with a successful risk- and quality-based manufacturing strategy.
It’s déjà vu all over again
Where does the time go? It is very hard for me to believe that I am already writing for the final issue of the year, looking back over 2011 and planning for 2012.
Impact of Ageing
Despite the fact that Europe's population is ageing rapidly, the region is astonishingly still underprepared for dealing with the health-related effect of this demographic trend.
Easy on the Alcohol!
Careful mixing during a product's distillation can help avert trouble from a strong concoction.
Super Fast Pharma
British racing car company and GlaxoSmithKline team up on a winning formula for innovation.
Passion, Innovation, and Loss
At a time when the industry is struggling with innovation, it might do well to learn a lesson from a few great innovators.
Turning around Pharmaceutical Manufacturing in the US
The authors propose a plan to keep the US pharma industry afloat and in the lead.
Threats and Opportunities in Cardiovascular Health
With the cardiovascular disease burden in Europe increasing, policymakers, regulators and other healthcare stakeholders are seeking to raise awareness and lessen the threat.
Managing Business Risks During a Merger or Acquisition
Getting the most value out of M&As requires proper upfront legwork.
Time is of the Essence
Letting contamination build up can cause multiple headaches.
Advancing with the Times
Despite new hurdles, industry must move forward and fulfill its mission.
Europe Edging Towards Electronic Prescribing
Electronic prescribing has grown strongly in the US but its future as a European-wide approach in healthcare has been uncertain; new regulatory interest could change the playing field.
Taking It For Granted
As editor of Pharmaceutical Technology Europe, I often have the opportunity to visit the sites of a wide variety of companies within the industry. Though differing vastly in the technologies and staff they employ, they all share one thing in common for me: the "you learn something new every day!" factor.
Knowing is Half the Battle
Being aware of a forthcoming inspection or how a product was made can make a huge difference.
Retrospection and Introspection at FDA
A report commissioned by FDA evaluates the QbD program.
Where in the World is the US Pharmacopeia?
After a series of structural changes, the author wonders whether USP is undergoing an identity crisis. USP CEO Roger L. Williams responds.
Biosimilars or Bust
Are biosimilars the next big thing or just the next big bubble?
Movin' On Out
Visiting a new site or going down memory lane may not get you where you want to go.